AngioJet rheolytic thrombectomy in patients with thrombolysis in myocardial infarction thrombus grade 5: an observational study.

Sci Rep

Department of Cardiology, Sixth Medical Center of Chinese People's Liberation, Army General Hospital, 6 Fucheng Road, Haidian District, Peking, 100048, People's Republic of China.

Published: March 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The aim of this study was to evaluate the effectiveness and safety of AngioJet rheolytic thrombectomy among patients with high thrombus burden. Routine manual thrombus aspiration in patients with ST-segment elevation myocardial infarction (STEMI) does not improve clinical outcomes and was associated with an increased rate of stroke. However, the safety of mechanical thrombus aspiration is still unknown. This was a retrospective, single-center study involving 621 patients with Thrombolysis In Myocardial Infarction thrombus grade 5. The primary outcome was the composite of major adverse cardiovascular events (MACE) within 12 months. The safety outcome was stroke within 1-year. Propensity matching score was calculated due to the significant baseline differences between the AngioJet rhelytic thrombectomy group and the routine treatment group. AngioJet rheolytic thrombectomy was performed in 117 patients. After propensity-score matching, there was no significant difference both in the incidence of MACE (11.1% vs 17.9%, hazard ratio, 1.641; 95% confidence interval [CI] 0.822 to 3.277, p = 0.161) and the incidences of stroke (1.7% vs 2.6%, hazard ratio 1.522; 95% confidence interval [CI] 0.254 to 9.107, p = 0.646) between two groups at 1-year follow-up. In patients with Thrombolysis In Myocardial Infarction thrombus grade 5, AngioJet rheolytic thrombectomy did not improve clinical outcomes at 1 year. However, AngioJet rheolytic thrombectomy did not increase the risk of stroke in patients with high thrombus burden.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971501PMC
http://dx.doi.org/10.1038/s41598-022-09507-zDOI Listing

Publication Analysis

Top Keywords

angiojet rheolytic
20
rheolytic thrombectomy
20
myocardial infarction
16
patients thrombolysis
12
thrombolysis myocardial
12
infarction thrombus
12
thrombus grade
12
thrombectomy patients
8
patients high
8
high thrombus
8

Similar Publications

Background: Pharmacomechanical catheter-directed thrombolysis (PCDT) is commonly used to treat acute deep venous thrombosis (DVT). The AngioJet Rheolytic Thrombectomy (ART) device is a widely used option. However, previous serious adverse events led to an FDA black-box warning.

View Article and Find Full Text PDF

BackgroundCerebral venous sinus thrombosis (CVST) is rare but potentially life-threatening. Although systemic anticoagulation is the primary treatment, endovascular thrombectomy (EVT) or thrombolysis may be considered for refractory cases. Considering advanced techniques and device technology, we undertook an updated systematic review and meta-analysis to evaluate clinical and radiographic outcomes for treating CVST.

View Article and Find Full Text PDF

Percutaneous treatment of highly thrombotic coronary lesions is demanding, due to worse acute and long-term clinical outcomes. In this report, we describe a case series of six patients with ST-segment elevation myocardial infarction and high-thrombus-burden coronary lesions. All patients were treated with the AngioJet Solent Dista catheter, a rheolytic thrombectomy device designed for peripheral use.

View Article and Find Full Text PDF

Objective: This study aimed to examine the early clinical outcomes of AngioJet rheolytic thrombectomy (RT) in patients with acute bilateral iliofemoral deep vein thrombosis (IFDVT), with a specific focus on the incidence of post-thrombotic syndrome.

Methods: From March 2021 to August 2023, 16 consecutive patients with acute bilateral IFDVT treated with AngioJet RT at our center were evaluated. Primary outcomes include patency of the target veins, development of post-thrombotic syndrome, recurrent DVT, and procedure-related death.

View Article and Find Full Text PDF